Feedback
Settings

Settings

Goto Application

8,117 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07H AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 812
1.WO/2022/140845NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST COVID-19
WO - 07.07.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No PCT/CA2021/051873 Applicant VAL-CHUM, LIMITED PARTNERSHIP Inventor STAMATATOS, Leonidas
The present application relates to neutralizing antibodies or antigen-binding fragments thereof against betacoronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to nucleic acid(s) encoding such neutralizing antibodies or antigen-binding fragments thereof, and to mixture and compositions comprising such antibodies, antigen-binding fragments or nucleic acids. Methods and uses of the antibodies, antigen-binding fragments thereof, nucleic acid(s) or compositions, including therapeutic, diagnostic, and preventative methods and uses for betacoronavirus infections and related diseases such as COVID-19, are also described.
2.3202566NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST COVID-19
CA - 07.07.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No 3202566 Applicant VAL-CHUM, LIMITED PARTNERSHIP Inventor STAMATATOS, LEONIDAS
The present application relates to neutralizing antibodies or antigen-binding fragments thereof against betacoronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to nucleic acid(s) encoding such neutralizing antibodies or antigen-binding fragments thereof, and to mixture and compositions comprising such antibodies, antigen-binding fragments or nucleic acids. Methods and uses of the antibodies, antigen-binding fragments thereof, nucleic acid(s) or compositions, including therapeutic, diagnostic, and preventative methods and uses for betacoronavirus infections and related diseases such as COVID-19, are also described.
3.WO/2023/115220DRUG COMBINATIONS FOR INHIBITING CORONAVIRUS REPLICATION
WO - 29.06.2023
Int.Class A61K 31/138
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines, e.g. amantadine
135having aromatic rings, e.g. methadone
138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
 Appl.No PCT/CA2022/051888 Applicant INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE Inventor LAPLANTE, Steven
A combination comprising tilorone/nelfinavir; tilorone/molnupinavir; tilorone/remdesivir; tilorone/alfacalcidol; tilorone/clofazimine; tilorone/danazol; tilorone/manidipine; tilorone/sertraline; tilorone/trifluoperazine; remdesivir/hexachlorophene; remdesivir/mycophenolate; mycophenolate/hexachlorophene; mycophenolate/nelfinavir; or mycophenolate/nitazoxanide. This combination can be used for blocking the replication of a coronavirus in a coronavirus-infected cell, for treating an infection by a coronavirus in a subject, for treating a coronavirus-related disease in a subject, and/or for reducing the risk of developing a coronavirus-related disease or the severity of a coronavirus-related disease in a subject.
4.20080044814Oligonucleotides, reagents and amplification methods for detecting severe acute respiratory syndrome coronavirus
US - 21.02.2008
Int.Class C12Q 1/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
 Appl.No 10552327 Applicant Genome Institute of Singapore Inventor Ren Ee Chee

This invention provides oligonucleotides, reagents and amplification methods for detecting the severe acute respiratory syndrome coronavirus (SARS CoV). This invention also provides related compositions, kits, systems, and computers.

5.7776521Coronavirus isolated from humans
US - 17.08.2010
Int.Class C12Q 1/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
70involving virus or bacteriophage
 Appl.No 11748359 Applicant The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention Inventor Rota Paul A.

Disclosed herein is a newly isolated human coronavirus (SARS-CoV), the causative agent of severe acute respiratory syndrome (SARS). Also provided are the nucleic acid sequence of the SARS-CoV genome and the amino acid sequences of the SARS-CoV open reading frames, as well as methods of using these molecules to detect a SARS-CoV and detect infections therewith. Immune stimulatory compositions are also provided, along with methods of their use.

6.WO/2005/000234NOVEL CORONAVIRUS INHIBITORS
WO - 06.01.2005
Int.Class C07H 21/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
04with deoxyribosyl as saccharide radical
 Appl.No PCT/US2004/018858 Applicant SARS SCIENTIFIC CORP. Inventor LAI, Derhsing
An agent that inhibits interaction of an intergenic sequence of coronavirus with the coronavirus polymerase complex or component thereof as well as the use of said agent for inhibiting expression of said coronavirus and detecting coronavirus in a subject, as well as kits and compositions comprising such agents.
7.20090117537Method for detecting SARS coronavirus
US - 07.05.2009
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
 Appl.No 12136605 Applicant Eiken Kagaku Kabushiki Kaisha Inventor Minekawa Harumi

This invention provides: a method for detecting SARS pathogenic viruses with high sensitivity and rapidity for diagnosing severe acute respiratory syndrome (SARS); an oligonucleotide primer that can specifically hybridize with any nucleotide sequence constructed based on the nucleotide sequence of RNA polymerase of the SARS coronavirus; a method for nucleic acid amplification using such primer; a method for diagnosing infection with the SARS coronavirus via detection of nucleic acid amplification; and a kit for diagnosing SARS.

8.WO/2022/204770ANTIVIRAL COMPOUNDS, METHODS FOR THE MANUFACTURING OF COMPOUNDS, ANTIVIRAL PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR THE ORAL TREATMENT OF CORONAVIRUS INFECTION AND RELATED DISEASES THEREOF
WO - 06.10.2022
Int.Class C07H 19/167
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
16Purine radicals
167with ribosyl as the saccharide radical
 Appl.No PCT/BR2021/050136 Applicant NALLAR, Jaime Alberto Rabi Inventor NALLAR, Jaime Alberto Rabi
The present invention relates to antiviral compounds selected from cytokinins, their nucleosides and nucleotide analogs, and their prodrugs as inhibitors of viral RNA synthesis, or their salts, solvates, derivatives, or even combinations of aforementioned compounds, for prophylactic treatment, curative (therapeutic) or mitigative coronavirus infection, represented by human and veterinary coronavirus, SARS-CoV-2 and MHV, and for the treatment of individuals potentially exposed to COVID-19. The present invention also comprises the methods for the manufacturing of such compounds, the antiviral pharmaceutical composition containing the compounds of the invention, as well as the use of the compounds, combinations of compounds, and method for the prophylactic, curative (therapeutic) or mitigative treatment of coronavirus infection, represented by coronavirus, in especial SARS-CoV-2 and of patients with COVID-19, individual infected with SARS-CoV-2 or potentially exposed to this virus. The antiviral activity of the compounds of this invention against SARS-CoV-2 was greatly enhanced by inhibiting the 3'-5'-exonuclease. Synergistic results of MB-905, MB-801, MB-711, and MB-804 were obtained with either raltegravir or dolutegravir (acting as inhibitors of exonuclease - iEXO). The one-log (90%) inhibition of viral replication, obtained with the MBs alone, was enhanced to an additional log either by raltegravir or by dolutegravir. Similar synergetic results were observed with sofosbuvir and tenofovir. In contrast, the potency of remdesivir, a delayed-chain terminator, was not increased by iEXO.
9.20220144866Crystalline form of Remdesivir
US - 12.05.2022
Int.Class C07F 9/6561
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
FACYCLIC, CARBOCYCLIC, OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
9Compounds containing elements of Groups 5 or 15 of the Periodic System
02Phosphorus compounds
547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
6561containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
 Appl.No 17601493 Applicant Apotex Inc. Inventor Fabio E. S. Souza

The present invention provides a novel crystalline form of remdesivir, remdesivir Form APO-I, including remdesivir and dimethyl sulfoxide, compositions and processes for the preparation thereof, the use of this crystalline form in the treatment of a viral infection, and methods of treating viral infections using the same, and in particular, a viral infection caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2).

10.WO/2022/204777ANTIVIRAL COMPOUNDS, METHODS FOR THE MANUFACTURING OF COMPOUNDS, ANTIVIRAL PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR THE ORAL TREATMENT OF CORONAVIRUS INFECTION AND RELATED DISEASES THEREOF
WO - 06.10.2022
Int.Class C07H 19/167
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
16Purine radicals
167with ribosyl as the saccharide radical
 Appl.No PCT/BR2022/050120 Applicant CALIXTO, João Batista Inventor CALIXTO, João Batista
The present invention relates to antiviral compounds selected from cytokinins, their nucleosides and nucleotide analogs, and their prodrugs as inhibitors of viral RNA synthesis, or their salts, solvates, derivatives, or even combinations of aforementioned compounds, for prophylactic treatment, curative (therapeutic) or mitigative coronavirus infection, represented by human and veterinary coronavirus, SARS-CoV-2 and MHV, and for the treatment of individuals potentially exposed to COVID-19. The present invention also comprises the methods for the manufacturing of such compounds, the antiviral pharmaceutical composition containing the compounds of the invention, as well as the use of the compounds, combinations of compounds, and method for the prophylactic, curative (therapeutic) or mitigative treatment of coronavirus infection, represented by coronavirus, in especial SARS-CoV-2 and of patients with COVID-19, individual infected with SARS-CoV-2 or potentially exposed to this virus. The antiviral activity of the compounds of this invention against SARS-CoV-2 was greatly enhanced by inhibiting the 3'-5'-exonuclease. Synergistic results of the compounds according to the present invention were obtained from the combination with repurposed drugs.
# -